✦ LIBER ✦

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

✍ Scribed by Younes, A.; Oki, Y.; McLaughlin, P.; Copeland, A. R.; Goy, A.; Pro, B.; Feng, L.; Yuan, Y.; Chuang, H. H.; Macapinlac, H. A.

Book ID: 111651065
Publisher: American Society of Hematology
Year: 2012
Tongue: English
Weight: 664 KB
Volume: 119
Category: Article
ISSN: 0006-4971
DOI: 10.1182/blood-2012-01-405456

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 study of rituximab in newly diag

Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group

✍ Eichenauer, D. A.; Fuchs, M.; Pluetschow, A.; Klimm, B.; Halbsguth, T.; Boll, B. 📂 Article 📅 2011 🏛 American Society of Hematology 🌐 English ⚖ 96 KB

Brentuximab vedotin combined with ABVD o

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study

✍ Younes, Anas; Connors, Joseph M; Park, Steven I; Fanale, Michelle; O'Meara, Mega 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 211 KB

Phase 2 study of gemcitabine in combinat

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

✍ Yasuhiro Oki; Barbara Pro; Luis E. Fayad; Jorge Romaguera; Felipe Samaniego; Fre 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB 👁 2 views

## Abstract ## BACKGROUND. The management of recurrent or refractory Hodgkin lymphoma (HL) remains challenging. The objective of this phase 2 trial was to investigate the activity of gemcitabine in combination with rituximab in patients with recurring or refractory HL. ## METHODS. Patients were

Phase II Multicenter Study of Bendamusti

Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma

✍ Robinson, K. S.; Williams, M. E.; van der Jagt, R. H.; Cohen, P.; Herst, J. A.; 📂 Article 📅 2008 🏛 American Society of Clinical Oncology 🌐 English ⚖ 119 KB

Phase I study of interleukin-12 in combi

Phase I study of interleukin-12 in combination with Rituximab in patients with B-cell non-Hodgkin lymphoma

✍ S.M. Ansell; T.E. Witzig; P.J. Kurtin; J.A. Sloan; D.F. Jelinek; K.G. Howell; S. 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 98 KB

Rituximab plus cyclophosphamide, doxorub

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

✍ Cunningham, David; Hawkes, Eliza A; Jack, Andrew; Qian, Wendi; Smith, Paul; Moun 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 429 KB